Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA approves Boehringer's afatinib, companion diagnostic

FDA approved Gilotrif afatinib from Boehringer Ingelheim GmbH (Ingelheim, Germany) as a first-line treatment for metastatic

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE